Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Clears First-Of-A-Kind Breast Cancer Recurrence Test

This article was originally published in The Gray Sheet

Executive Summary

Dutch firm Agendia's MammaPrint test for predicting breast cancer recurrence set regulatory precedent Feb. 6 when it received 510(k) clearance

You may also be interested in...



Financings In Brief

Agendia plans IPO

Financings In Brief

Agendia plans IPO

Agendia Boasts Expanded Clearance, Reimbursement For Breast Cancer Test

Gene expression test maker Agendia will ramp up its U.S. marketing efforts after gaining expanded FDA clearance and Medicare coverage for its flagship MammaPrint breast cancer recurrence test

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel